Amryt Pharma clinical trials
Acquired by Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
The registry lists 5 studies whose lead sponsor is Amryt Pharma. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 22, 2026.
Before and after it joined Chiesi Farmaceutici S.p.A.
- First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- 3
- First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Amryt Pharma5 studies
Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Chiesi Farmaceutici S.p.A. studies →
- Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingNCT06484868Phase 4
Sponsor listed in the registry: Amryt Pharma · First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyTerminatedNCT06502990Phase 3
Sponsor listed in the registry: Amryt Pharma · First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- LOWER: Lomitapide Observational Worldwide Evaluation RegistryCompletedNCT02135705
Sponsor listed in the registry: Amryt Pharma · First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)CompletedNCT04681170Phase 3
Sponsor listed in the registry: Amryt Pharma · First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A.
- Global Lomitapide Pregnancy Exposure RegistryTerminatedNCT02399839
Sponsor listed in the registry: Amryt Pharma · First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A.